Research Topics
| LAWRENCE PAOLETTISummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIIIL C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
J Infect Dis 180:892-5. 1999..GBS types VI and VIII conjugate vaccines of the design presented may be important components of a multivalent GBS vaccine for use in regions where these serotypes predominate...- Glycoconjugate vaccines to prevent group B streptococcal infectionsLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
Expert Opin Biol Ther 3:975-84. 2003..Results from these preclinical and clinical studies strongly suggest that GBS conjugate vaccines will be effective in preventing diseases caused by GBS... - Neutralizing antibody induced in mice by novel glycoconjugates of human immunodeficiency virus type 1 gp120 and env2-3Lawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Infect Dis 186:1597-602. 2002..HIV-1 gp120-specific IgG with neutralizing activity against HIV-1 can be induced with conjugates containing gp120, env2-3, III, and TT... - Vaccines to prevent neonatal GBS infectionLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Semin Neonatol 7:315-23. 2002..Moreover, human antibodies elicited by the conjugate vaccines are functionally active both in vitro and in animal models of invasive GBS disease... - Conjugate vaccines against group B Streptococcus types IV and VIILawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Infect Dis 186:123-6. 2002..If needed, types IV and VII CPS conjugate vaccines of the design described can be added to the formulation of a multivalent GBS vaccine... - Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigenL C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, 181 Longwood Avenue, Boston, MA 02115, USA
Vaccine 20:370-6. 2001..In addition, carrier-specific IgG was also measured in serum from vaccinated mice. These data suggest that the rdHBcAg and DTm may be effective carriers for GBS CPSs... 
A serotype VIII strain among colonizing group B streptococcal isolates in Boston, MassachusettsL J Paoletti
Clinical Microbiology Department, Channing Laboratory, Boston Massachusetts 02115, USA
J Clin Microbiol 37:3759-60. 1999..Whereas serotypes Ia, Ib, II, III, and V are prevalent in the United States, types VI and VIII predominate in Japan. Recently, a serotype VIII strain was detected among 114 clinical GBS isolates from a Boston, Mass., hospital...- Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccinesL C Paoletti
Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 69:6696-701. 2001.... - Potency of clinical group B streptococcal conjugate vaccinesL C Paoletti
Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Vaccine 19:2118-26. 2001..A reconstituted GBS conjugate vaccine remained potent and antigenically intact after 31 days' storage at 2-8 degrees C. These data suggest that lyophilization in the presence of sucrose extends the potency of GBS conjugate vaccines... - Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugateL C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
J Infect Dis 181:653-8. 2000..These preclinical studies provide further evidence for effective immunogenicity of GBS conjugate vaccine and efficient transport of functionally active maternal antibody... - Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccinesHsiao Hui Yang
Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
Infect Immun 75:3455-61. 2007..These results suggest that the rBCP(DeltaIgA) could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP... - Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier proteinHsiao Hui Yang
Department of Medicine, Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Vaccine Immunol 15:1035-41. 2008..Thus, the potential exists for the inclusion of rAlp3 in a GBS vaccine formulated to provide multiserotype coverage... - Identification of novel cps locus polymorphisms in nontypable group B StreptococcusSrinivas V Ramaswamy
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
J Med Microbiol 55:775-83. 2006..Collectively, genetic and immunologic analyses revealed that these NT isolates expressing R1, R4 proteins have a genetic profile consistent with that of type V, an emergent, antigenically diverse and increasingly prevalent GBS serotype... - Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cellsHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Hum Vaccin 4:370-4. 2008..These results represent the first important step in developing a standardized, high-throughput OPA that could be used to assess the functional activity of vaccine-induced antibody and potentially serve as a surrogate of efficacy... - Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbitsLawrence C Paoletti
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Hum Vaccin 4:435-43. 2008..e., it was non-teratogenic). In addition, that III-TT lot 3-1-96 was found to be safe and immunogenic in two clinical studies involving healthy non-pregnant adults supports a clinical evaluation of this vaccine in pregnant women... - Molecular characterization of nontypeable group B streptococcusSrinivas V Ramaswamy
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA
J Clin Microbiol 44:2398-403. 2006..These data shed new light on the antigenic complexity of NT GBS isolates, information that can be valuable in the formulation of an effective GBS vaccine... - A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B StreptococcusHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Hum Vaccin 5:461-6. 2009..Quantitative functional antibody determinations using the flOPA may serve as a surrogate measure of GBS vaccine effectiveness in lieu of traditional phase 3 efficacy trials... - The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxisAnushua Sinha
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
Vaccine 23:3187-95. 2005..Maternal GBS vaccination is predicted to prevent more cases of neonatal GBS disease than current practice and would prevent approximately one in 25 very preterm births... - Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14Hilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 70:1724-38. 2002..When present, these vaccine-induced cross-reacting antibodies conferred in vitro antibody-mediated opsonophagocytosis and killing of both GBS III and Pn14, two pathogens that cause invasive disease in young infants... - Adherence to, invasion by, and cytokine production in response to serotype VIII group B StreptococciHiroshige Mikamo
Channing Laboratory, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 72:4716-22. 2004..These results suggest differences in immune responses to infection with GBS serotypes III and VIII... - Oxygen regulates invasiveness and virulence of group B streptococcusAtul K Johri
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 71:6707-11. 2003..8 h, with oxygen) was more virulent in neonatal mice than was GBS grown under suboptimal invasion conditions (t(d) of 1.8 h, without oxygen), suggesting a positive association between in vitro invasiveness with DIVAS and virulence... - Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switchingHilde Kari Guttormsen
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Institute for Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:5903-8. 2008..Targeted chemical engineering of a carbohydrate to create a molecule less like host self may be a rational approach for improving other glycoconjugates... - Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont Bacteroides fragilisMichael J Coyne
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:13099-104. 2008.... - Growth rate and oxygen regulate the interactions of group B Streptococcus with polarized respiratory epithelial cellsAtul K Johri
Channing Laboratory, Department of Medicine, Breigham and Women's Hospital, Harvard Med School, 181 Longwood Avenue, Boston, MA 02115, USA
Can J Microbiol 51:283-6. 2005..Growth rate and oxygen level strongly influence the interaction of GBS with polarized RECs and likely GBS pathogenicity... - Transcriptional and proteomic profiles of group B Streptococcus type V reveal potential adherence proteins associated with high-level invasionAtul K Johri
Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Infect Immun 75:1473-83. 2007..Collectively, these data increase the number of potential GBS adherence factors and also suggest a role for these surface-associated proteins in initial pathogenic events... - Group B Streptococcus: global incidence and vaccine developmentAtul Kumar Johri
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
Nat Rev Microbiol 4:932-42. 2006..This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens... - Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and IIICarol J Baker
Sections of Infectious Diseases, Department of Pediatrics, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
J Infect Dis 188:66-73. 2003..These results support the feasibility of a multivalent vaccine for the 5 prevalent invasive disease-causing GBS CPS serotypes... - Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adultsCarol J Baker
Section of Infectious Diseases, Department of Pediatrics, Room 302A, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States
Vaccine 25:55-63. 2007..V-TT vaccine-induced antibodies promoted opsonophagocytic killing of type V GBS and avidity maturation of V CPS-specific IgG... - Identification of a universal Group B streptococcus vaccine by multiple genome screenDomenico Maione
Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
Science 309:148-50. 2005..Multigenome analysis and screening described here represent a powerful strategy for identifying potential vaccine candidates against highly variable pathogens... - Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccinesCarol J Baker
Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
J Infect Dis 189:1103-12. 2004..Infections caused by group B streptococcal (GBS) type V are increasingly common. Capsular polysaccharide (CPS)-protein conjugate GBS vaccines are immunogenic in healthy adults, but type V vaccines have not previously been tested...
Research Grants
- Bacterial Vaccine Antigen DiscoveryLAWRENCE PAOLETTI; Fiscal Year: 2006..Aim 2). Findings from these studies utilizing this unique approach to vaccine antigen discovery could be directly applied to other bacterial pathogens. ..
- Development of a Global GBS VaccineLAWRENCE PAOLETTI; Fiscal Year: 2007..This work will lead to a vaccine effective in preventing GBS diseases worldwide. ..